TALZENNA Pfizer Australia Pty Ltd
Product name
TALZENNA
Sponsor
Accepted date
May-2023
Active ingredients
talazoparib tosilate
Proposed indication
For the treatment of patients with deletrious germline breast cancer suscepibility gene mutation.
Application type
C (new medicine)
Publication date
May-23